On December 19, 2005, The U.S. Food and Drug Administration denied a petition by the Cognis Corporation. Cognis wanted to the right to make the following claim for their lutein product:
“Consumption of 12 mg of Xangold® lutein esters per day may reduce the risk of age-related macular degeneration and cataract formation. FDA has determined that the evidence is supportive, but not conclusive, for this claim. This food/dietary supplement provides __ mg lutein esters per serving.”
Coenzyme Q10 (CoQ10) is a vitamin-like substance used in the treatment of a variety of disorders primarily related to suboptimal cellular energy metabolism and oxidative injury.
Prices of CoQ10
supplements have skyrocketed recently
because of increased demand and limited production capacity. The main
surge in demand occurred as word got out that ‘statin’ drugs
(used to decrease cholesterol in the blood) have a side effect
of causing the depletion of CoQ10 throughout the body. Large
numbers of cardiovascular patients began buying CoQ10 supplements.